Press Releases

BioMS Medical Commences U.K. Patient Enrollment in Multiple Sclerosis Trial

- Company Expands Pivotal Phase II/III MS Trial Into Europe -

Edmonton, Alberta, July 21, 2005 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the first patients in the United Kingdom have been enrolled in its pivotal Phase II/III clinical trial for MBP8298, a proprietary synthetic peptide for the treatment of secondary progressive MS. Patient enrollment is now active across both Canada and the U.K.

“The successful expansion of our pivotal trial into Europe is an important milestone for BioMS. The European market represents a significant portion of MS patients globally with approximately 85,000 MS patients in the U.K. and 450,000 across Europe”, said Mr. Kevin Giese, President of BioMS Medical. “The expansion of this trial into Europe is expected to continue with the addition of another jurisdiction in the near future.”

The trial is expected to enroll up to 553 patients and will be a double-blind, placebo-controlled study. Patients will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS) in the previously identified responder group, patients with immune response genes HLA-DR2 or HLA-DR4. Patients with the immune response genes, HLA-DR2 or HLA-DR4, account for up to 75% of the MS patient population.

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.